Establishment of a human fusion partner for making human T-T hybridomas which can grow in serum free medium

A new human fusion partner, ICLU-T was established for making human T-T hybridomas. Some 6-thioguanine resistant (6-TG^r) clones were separated from human T cell acute lymphocytic leukemia, PEER. The fastest growing clone of the 6-TG^r cells was scaled up and was cultured in serum free medium. The clone that proliferated most quickly in the serum free medium was separated and named ICLU-T. When ICLU-T was fused with human peripheral blood lymphocytes by using only polyethylene glycol, the viability of fused cells was below 20% efficiency was 0.01∼0.02 per 10⁵ parent cells. Whereas, the combined use of 1% and the fusion efficiencies over 0.2 per 10⁵ parent cells on the average. In a total of 34 clones of obtained hybridomas, there were 25 CD2 positive clones. CD4 positive or CD8 positive clones of the CD2 positive clones were 12 and 5 clones, respectively. Further, 4 clones of all hybridomas were CD19 positive, and one clone of these hybridomas was an Ig producer. These obtained hybridomas could proliferate in serum free medium.